Which subsets of GCA pt might benefit most from upadacitinib? Sub-analysis from SELECT-GCA presented today: 💥Both re
Tweet Content
Which subsets of GCA pt might benefit most from upadacitinib?
Sub-analysis from SELECT-GCA presented today:
💥Both relapsing and refractory disease
💥Pt w hx of PMR
💥Non-smokers
💥No hx ischemic eye dz
In general, most subgroups still favor UPA
@RheumNow #ACR24 Abst 1695 https://t.co/pX5hcX4TmR
Show on Archive Page
On
Display in Search Results
On
PDQ
Off